According to new findings published in mBio, the vaccine produced potent neutralizing antibodies among preclinical models and also prevented infection and disease symptoms in the face of exposure to SARS-CoV-2 (the virus that causes COVID-19).
The AMC is the COVAX Facility’s mechanism to provide donor-funded vaccines to lower-income countries.
This action-based focus - called biological activity-based modeling (BABM) - forms the core of a new approach developed by National Center for Advancing Translational Sciences (NCATS) researchers and others.
The findings, which were announced in January and have now been peer-reviewed and published in the New England Journal of Medicine, come from the REMAP-CAP trial, which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).
T-cell immunity is one of the key mechanisms used by the human body to fight virus infections. The staging ground for cell immunity development is the presentation of virus peptides on the surface of infected cells.
